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INTRODUCTION 
 Carcinoma of the uterine cervix is the second most common cancer 
among global women and the first most common cancer in Indian 
women. The main stay of treatment in locally advanced inoperable 
carcinoma Cervix is combination of external beam radiotherapy (EBRT) 
and intracavitary brachytherapy ICBT. Brachytherapy forms an integral 
part and cornerstone of radiation therapy for both the local control rates 
and toxicities.  
 Intracavitary brachytherapy has a high therapeutic index by 
delivering a high dose to the primary cervical lesion and lower dosed to 
critical structures namely, bladder, rectum resulting in increased local 
control and survival without increase in toxicity. However, the dose 
deliver to critical structures are difficult to quantify accurately.  
 In present Indian  Scenario dosimetry of ICBT is carried out using 
orthogonal radiographs where point doses to critical structures are 
calculated according to the ICRU 38
(1a)
 recommendations. This traditional 
methods have yielded high control rates of tumor and acceptable 
complications of normal tissue. But the point doses may not represent the 
dose received by the volume of the organs. It has been reported that the 
ICRU point doses do underestimate doses received by the rectum and 
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bladder.
(4-7) 
The ratio of maximum dose to the rectum and bladder from 
the CT planning to that obtained from radiograph based planning has a 
wide range. 
(4-6)
  
 STATE OF ART - Over the previous two decades, with the 
advent of better imaging modalities (USG, CT, MRI, PET scan) 
Radiation technology and its successful implementation in external beam 
radiation therapy (3D CRT, IMZRT, IGRT etc) is a success story today. 
However, implementation of these advances in brachytherapy has been 
rather sluggish. Published data on 3D Image based brachytherapy in 
cervical cancers from India is sponse but it does not preclude its use. 
 In developing countries including India, locally advanced cervical 
cancer being a major problem - appropriate, adequate and quality 
treatment to all patients is the key to success. In India, there has been a 
rapid improvement in radiation facilities like CT scanner / simulators for 
RT planning in government sectors. There is an urgent need to generate 
robust data on CT, MRI-3D image based brachytherapy planning and 
suitable evidence through clinical studies to resolve the issues.   
 In an attempt to achieve a better understanding of the treatments, 
we compared two treatment planning methods based on orthogonal 
radiographs and CT Plan. The comparison was based on point doses 
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defined by the orthogonal X-rays and dose volume histrograms (DVHs) 
from 3D planning (CT Plan).  
 I hope the study will give us accurate understanding of the dose 
received by dose limiting structures like bladder and rectum. It may 
contribute in improving the therapeutic index both in terms of treatment 
outcome and reducing the complications. 
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REVIEW OF LITERATURE 
EPIDEMIOLOGY 
INCIDENCE 
There is a wide geographical variation in incidence of cancer 
cervix. The highest incidence rates are reported from Asia, South 
America and Africa. In India cancer .cervix is the commonest malignancy 
among women with an incidence of over 100,000 new cases annually. It 
constitutes 20 - 50% of all cancers detected in our women. The AAR of 
cancer cervix among the various cancer registries of the country ranges 
from 19-44 per 100,000 women (mean 31.4 per 100,000 women.) 
According to MMTR 2007 (Madras Metropolitan Tumor Registry) 
among 2632 women cancer patients 380 were CA cervix patients. The 
incidence rate in 2007 was 16.4 per lacks. The peak incidence of cervical 
cancer occurred between 55 to 59 years of age. A significantly decreasing 
trend in incidence of cervical cancer was forth coming during 1988-2008 
with an average annual change of 2%. 
Most of the women belong to lower socioeconomic stratum. 
The predisposing factors include  
1. Female sexual behavior 
• Sexual intercourse - This is the major prerequisite for the development 
of cancer cervix. 
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• Age at first coitus - Women who start their sexual life at an early age 
particularly before 18 years are at higher risk (1.4 to 1.9 times 
increased risk) of developing cancer cervix. 
• Multiple sexual partners - Cancer cervix patients usually give a history 
of multiple sexual partners. The risk is doubled for women with 6 
sexual partners. 
• Parity - Risk factors related to parity include first childbirth at an early 
age and multiparity. 
2. Male sexual behavior (high risk male) 
High risk male sexual habits, the presence of which is associated 
with a higher incidence of cancer cervix in their spouses are 
• Sexual promiscuity: >3 extra marital partners 
• History of sexually transmitted disease 
• History of cancer penis (increases risk of cancer cervix in wife by 3 - 6 
times) 
• History of cancer cervix in first wife (increases risk of cancer cervix 
second wife 2 fold) 
• Poor penile hygiene, Causative role of cigarette smoking in male and 
the protective effect of male circumcision are controversial. 
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3. Lower socio-economic group 
Women from a lower socio-economic group have a higher 
incidence (about 3 fold) of cervical malignancy due to early marriage, 
early onset of sexual life and lack of genital hygiene. 
4. Viral etiology 
• HPV (Human Papilioma Virus) - Among various agents, the HPV 
virus is considered to be the most likely candidate for etiological 
responsibility. Infection with HPV serotypesl6 & 18 are highly 
prevalent in CIN-II, III and invasive cancer cervix. HPV exerts its 
effect by P-53 gene suppression and inhibition of cell mediated 
immunity. 
• HIV (Human  immune deficiency virus)  - Women who  are HIV 
positive have a 10 fold risk of cervical cancer in comparison with 
matched controls. Prevalence of cancer cervix in HIV positive patients 
below the age of 50 years is 19%. 
• HSV (Herpes simplex virus) - There is much data suggesting an 
association between cancer cervix and HSV but no conclusive proof is 
available. 
5. Smoking - Smoking appears to double the risk of developing cervical 
cancer. 
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NATURAL HISTORY 
Squamous cell carcinoma of the uterine cervix originates at the 
squamo columnar junction (transformation zone) of the endocervical 
canal and portio of the cervix. The lesion is frequently associated with 
severe cervical dysplasia and carcinoma in situ usually progressing over 
10 to 20 years. The malignant process breaks through the basement 
membrane of the epithelium and invades the cervical stroma. The lesion 
may eventually manifest as superficial ulceration, exophytic tumor in the 
exocervix, or extensive infiltration of the endocervix. Later on the tumor 
may spread to the vaginal fornices or to the paracervical and parametrial 
tissues with eventual direct invasion of the bladder, rectum or both. 
The cervix is richly supplied by lymphatics. The cervix is drained 
by parametrial, cardinal and uterosacral ligament routes into the 
following regional lymph nodes: Parametrial, Paracervical, Obturator, 
Internal iliac (hypogastric), External iliac, Common iliac, Sacral, and 
PresacraL The lymph nodes involvement depends on the tumor bulk and 
the depth of penetration. The probability of lymph node metastasis in 
FIGO stages IA1, IA2, IB, IIB and IIIB is approximately 1%, 5-8%, 15%, 
30%, 50% respectively. 
Hematogenous spread occurs through the venous plexus and 
paracervical veins. Most frequently involved sites are lung, paraaortic 
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lymph nodes, spines (lumbar, thoracic), abdominal cavity, supraclavicular 
lymph nodes. Distant metastasis is mostly seen in cases of advanced 
disease and in recurrences. 
CLINICAL PRESENTATION 
• CIS and early invasive carcinoma can be detected before it 
becomes symptomatic by cytological smears. 
• Frequent and first manifestation of cancer cervix is post coital 
bleeding which may increase to metrorrhagia or menorrhagia. 
• Serosanguineous or yellowish foul-smelling discharge is also 
noted. 
• Fatigue, weakness related to anemia if chronic bleeding occurs. 
• Pain in pelvis or hypogastrium due to tumor necrosis or associated 
pelvic inflammatory disease. 
• Lumbosacral pain due to para aortic node involvement. 
• Hematuria, rectal bleeding may appear due to bladder or rectal 
invasion by the tumor. 
PATHOLOGY 
Over 90% of tumors are squamous cell carcinomas. There are 3 
types: large cell keratinizing and non-keratinizing and small cell type. 
They are sub divided according to the degree of differentiation into well, 
moderately or poorly differentiated. Verrucous carcinoma is a variant of a 
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very well differentiated SCC which has a tendency to occur locally but 
not to metastasize. 
Adenocarcinoma arises from the cylindrical mucosa of the 
endocervix or the mucous secreting endocervical glands. Approximately 
they form 7-10% of cervical tumors. Mucinous is the most common sub 
type. Other sub types are endometrioid adenocarcinoma, clear cell 
adenocarcinoma, adenosquamous carcinoma, adenoid cystic carcinoma, 
and adenoid basal cell carcinoma. 
Small cell carcinoma, neuroendocrine tumors, undifferentiated 
carcinomas, lymphomas and sarcomas are also reported rarely. 
SCREENING RECOMMENDATIONS 
The American Cancer Society has recommended that 
asymptomatic women 20 years of age and older and those younger than 
20 years who are sexually active should have Papanicolaou smear 
annually for 2 consecutive years, if normal at least one every 3 years until 
the age of 65 years. 
  The American College Of Obstetricians and Gynecologists 
strongly recommend that Pap smear should be obtained on an annual 
basis. 
High risk women should undergo annual Pap smear examination. 
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DIAGNOSTIC WORK-UP FOR CERVICAL CANCER GENERAL 
History, Physical examination including bimanual pelvic and rectal 
examinations. 
DIAGNOSTIC PROCEDURES 
Cytological smears (Pap smear if no bleeding), Colposcopy, 
Conization (sub clinical tumor), Punch Biopsies (edge of gross tumor, 4 
quadrants), Dilatation and curettage 
Cystoscopy and Rectosigmoidoscopy (stages IIB, III, IVA) 
RADIOGRAPHIC STUDIES STANDARD 
Chest radiography, Intravenous pyelography, Barium enema 
(stages III and IVA and in earlier stages if symptomatic) Ultrasound 
abdomen 
CT scan abdomen and pelvis or MRI, Lymphangiography, PET 
scan (optional – if affordable) 
LABORATORY STUDIES 
Complete blood count, Blood chemistry, Urinalysis 
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STAGING 
TNM FIGO  
TX  Primary tumor cannot be assessed 
TO  No evidence of primary tumor 
TIS * Ca in situ 
Tl I Cervical Ca confined to uterus 
T1a IA Invasive Ca diagnosed only by microscope 
Tlal IA1 Stromal invasion not greater than 3mm the 
depth   and 7mm   horizontal spread 
Tla2 IA2 Stromal invasion >3.mm and not more than 
5 mm with 7mm or less horizontal spread. 
T1b IB Clinically visible lesions confined to 
Cervix or microscopic extension > IA 
Tlbl IBl Visible lesion 4cm or less in greater 
dimension 
Tlb2 IB2 Visible lesion > 4cm in greatest dimension 
T2 II Tumor invades beyond uterus but not to 
pelvic wall or lower 1/3 vagina 
T2a IIA IIA1 
       IIA2 
Without parametrial invasion 
IIA1 clinically visible less than 4 c.m. 
IIA2 Clinically visible more than 4 cm. 
T2b JIB With parametrial invasion 
T3 III Tumor extends to pelvic wall or involves 
lower 1/3 vagina causes hydronephrosis or 
non functioning kidney 
T3a IIIA Tumor involves lower 1/3 vagina not 
extending to pelvic wall 
T3b IIIB Tumor    extending    to    pelvic     walls     
or     causing hydronephrosis or non- 
functioning kidney 
T4 IVA Tumor invades the mucosa of the bladder 
or rectum and or extends beyond the true 
pelvis 
N0  No regional lymph nodes metastasis 
N1  Regional lymph nodes metastasis 
M0  No distant metastasis is found. 
M1 IVB Distant metastasis 
* FIGO staging no longer includes stage 0 (TIS) 
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OVERVIEW OF TREATMENT POLICY IN CANCER CERVIX 
All the three standard modalities of oncology namely radiation, 
surgery and chemotherapy have stamped their role in the treatment of 
different stages of the disease. 
ROLE OF SURGERY IN CANCER CERVIX THERAPY 
The role of radical surgery is limited to pre-invasive and early 
stages of invasive growth. 
ROLE OF RADIATION IN THE THERAPY OF CANCER 
CERVIX 
Right from the time of its discovery nearly a century ago, 
radiotherapy has been the predominant modality used in the therapy of 
cancer cervix. Radiation finds a place in the management of all stages of 
the disease. In early-disease it is an effective curative alternative to 
surgery. In locally advanced disease it is the primary curative modality. 
In metastatic disease radiation palliates local and distant, complications. 
Radiation is delivered as brachytherapy alone, as ICA (intracavitary 
application) in stage I disease or with ideally sequenced combinations of 
external beam radiation (EBRT) and brachytherapy in other stages. As 
the size of the lesion and the proportion of the cervix involved increases, 
the risk of lymph node involvement also increases and one has to irradiate 
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the whole pelvis, covering the primary tumor, its local extension within 
the pelvis and the pelvic lymph nodes in contiguity. 
A homogenous dose distribution over such a large volume can be 
achieved only by teletherapy. The external beam radiation is followed by 
ICA to achieve the highest local control rate possible and this sequence is 
also ideal in that the tumor shrinkage caused by the initial EBRT will 
bring the anatomy to near normal resulting in an optimal and uniform 
dose distribution from a subsequent ICA. EBRT is delivered before 
brachytherapy in patients with bulky primary tumors, exophytic bleeding 
tumors, necrotic or infected tumors and tumors with parametrial 
involvement. 
PRINCIPLE OF EBRT 
EBRT aims at producing a homogenous dose to the target volume 
which includes the primary tumor (uterus with cervix), paracervical and 
parametrial tissue, vagina if involved and regional lymph nodes. EBRT 
can be delivered by conventional fractionation or by hyperfractionated 
radiotherapy techniques. 
 PRINCIPLE OF ICA 
ICA delivers a very high dose to the central tumor volume 
including the cervix and adjacent tissues with maximum tumor control 
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without crossing the tolerance of sujrounding normal tissue. This is 
possible because the normal uterus and vaginal vault are relatively radio-
resistant and tolerate relatively high doses of radiation and there is a rapid 
fall of dose at a distance from the cervix protecting the rectum, bladder 
and small bowel. 
Intracavitary brachytherapy can be delivered by low dose rate 
(LDR), moderate dose rate (MDR) and high dose rate (HDR) dose 
delivery systems. The dose rate of LDR is 0.4- 2Gy/ hr., MDR is 2-12 
Gy/hr. and HDR is > 12 Gy/hr. 
As many studies have demonstrated comparable local control, 
survival and morbidity HDR-ICA has been widely incorporated as a 
component in the treatment of cancer cervix. 
THE AMERICAN BRACHYTHERAPY SOCIETY DOSE 
RECOMMENDATIONS
28
 
The ABS recognizes that the whole pelvic EBRT dose varies from 
institution to institution. The HDR fraction size and number depends on 
the EBRT dose. The ABS recommends keeping the total treatment 
duration to less than 8 weeks so it is recommended to interdigitate HDR 
applications during EBRT (but EBRT is not given on the day of HDR). 
When EBRT and HDR brachytherapy are combined, the goals are to treat 
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Point A to an LDR equivalent of 80-85 Gy for early stage disease and 85-
90 Gy for advanced stage. Early disease is defined as nonbulky stage I/II, 
less than 4cm diameter; advanced stage is defined as greater than 4 cm or 
stage III B. The pelvic sidewall dose recommendations are 50-55 Gy for 
smaller lesions and 55-60 Gy for larger lesions. 
Suggested doses of EBRT and HDR brachytherapy in treating late 
cervical cancer 
EBRT (Gy) @ 1.8 
Gy/# 
No. of HDR fractions HDR dose/fraction 
45 5 6.5 
45 6 5.8 
50.4 4 7.0 
50.4 5 6.0 
50.4 6 5.3 
 
SOURCES FOR HDR INTRACAVITARY BRACHYTHERAJPY 
A radionuclide with high specific activity (activity per unit mass; 
Ci/g) is needed so that treatment dose rates of at least 12 Gy/hr can be 
achieved without sacrificing the level of miniaturization needed to 
support intracavitary and interstitial brachytherapy. A source no larger 
than lmm in diameter by 4mm long with an exposure rate of at least 
lR/sec at lcm is required. The exposure rate achieved by a small source 
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depends on the chemical form (i.e. relative mass of non radioactive 
atoms) of the source, its density, exposure rate constant of the 
radionuclide and photon self absorption. 
SOURCES 
The need for high specific activity sources limits the number of 
radio isotopes suitable for HDR remote after loaders. Most HDR units use 
Iridium-192 (
l92
Ir) or cobalt 60 (
60
Co). 
I92
Ir offer smaller source sizes but 
sources must be changed frequently. Most centers exchange their 
192
lr 
sources every 3 or 4 months (half life 73.8 days) whereas a similar decay 
fraction for 
60
CO takes 5-8 years (half life 5.26 years. 
60
Co is used as an 
intracavitary HDR sources in the form of small spherical pellets emits 
two high energetic 7 rays (1.17 &1.34 MeV). The smaller 
192
Ir sources 
permit access to more body sites via interstitial or intraluminal 
applications. 
60
Co and Cesium- 137(
137
Cs) sources are suitable only for 
intracavitary and some intraluminal treatment such as for esophagus. 
Based solely on specific activity considerations 
192
Ir is the optimal 
choice for HDR brachytherapy and is the widely used radionuclide for 
this application. 
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HIGH DOSE RATE- Iridium-192 
Iridium-192 (alloy of 30% Ir and 70% Pt) sources are fabricated in 
the form of thin flexible wires which can be cut to desired lengths. Nylon 
ribbons containing iridium seeds 3 mm long and 0.5 mm in diameter, 
spaced with their centers 1 cm apart, are also commonly used. Both the 
wires and the seed ribbons are quite suitable for the after loading 
technique. 
192
Ir has a complicated γ ray spectrum with an average energy 
of 0.38 MeV (0.136-1.06MeV) Because of the lower energy, these 
sources requires less shielding for personnel protection. The Exposure 
rate constant (τ) for 
192
Ir is 4.69 Rcm
2
 h
-1
 mCi
-1
. 
REMOTE AFTERLOADER 
Remotely controlled after loading devices are now available that 
eliminate the direct handling of the radioactive sources. A HDR remote 
after loading unit contains a single source of high activity (~10 Ci or 370 
GBq). 
The 
192
Ir source used in HDR is a small line source welded to the 
end of a flexible drive cable. The cable with the source attached at the 
end is also called source wire. The after loader drives the source to 
programmed location in the applicator (dwell positions) and holds it in 
place there for programmed intervals (dwell times). The term stepping 
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source is applied to the design. The possibility of programming the dwell 
position and times individually permits more control over the dose 
distributions and is the prerequisite for many of the optimization 
techniques. The dimensions of the source vary between 0.3 to 0.6 mm in 
diameter and 3.5 to 10 mm in length, depending on the HDR model. The 
source wire, when not extended, is stored in a shielded safe of the HDR 
unit. In compliance with the NRC regulations, the leakage radiation levels 
outside the unit do not exceed 1 mR/h at a distance of 10 cm from the 
nearest accessible surface surrounding the safe with the source in the 
shielded position. 
The HDR unit is equipped with several channels and an indexer 
system to direct the source to each channel. Applicators or catheters 
implanted in the patient are connected to the channels by catheters called 
transfer tubes or transfer guides. Before the active source wire is extended 
for treatment, a dummy wire is extended to verify that the path is clear of 
any obstruction. 
The source wire (or dummy wire) can be advanced or retracted 
through individual channels, transfer tubes and applicators by a remote 
computer controlled drive mechanism consisting of stepper motors. The 
positioning of the source at the programmed dwell positions in the 
applicators is accomplished in precise increments by the stepper motors. 
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The positioning accuracy of the source is specified at ±1 mm. The dose 
control precision is provided by a 0.1-second dwell time resolution. 
Some of the commercially available remote afterloading systems 
include the Curietron, the micro-Selectron, the Gamma Med, Omnitron 
2000 and Buchler unit. 
HIGH DOSE RATE APPLICATORS 
Brachytherapy applicators used for low dose rate implants can also 
be used for HDR. For example, some of the most commonly used 
applicators, for a variety of HDR applications, are: 
Fletcher-Suit or Fletcher-Suit-Delco's 
These applicators are used for the treatment of gynecological 
malignancies of the uterus, cervix and pelvic side walls. The applicator 
set typically consists of three rigid intrauterine tandems, with curvature of 
15-, 30-, and 45-degree angles, and a pair of ovoids or colpostats with 
shields in place to reduce dose to rectum and bladder. The tandem and the 
ovoids (or the colpostats) are made of stainless steel and then secured to 
hollow handles to permit afterloading of the sources. The colpostats in the 
Fletcher-Suit applicator are partially shielded at the top and the bottom to 
provide some protection to bladder and rectum. However, dosimetrically 
it is difficult to demonstrate the extent of protection actually provided by 
these shields. 
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DOSE SPECIFICATION: CANCER OF THE CERVIX 
No single system has been devised that can meet all the criteria of 
dose specification, three systems are described that are most commonly 
used in many forms and combinations. 
A.  Milligram-Hours 
One of the oldest systems of dose specification for the 
brachytherapy treatment of cervix is the milligram-hours, that is, the 
product of total source strength and the implant duration. It lacks the 
information on source arrangement, position of tandem relative to the 
ovoids, packing of the applicators, tumor size, and patient anatomy, with 
large uncertainties in the dose distribution from patient to patient. 
Although the milligram-hours are an  important treatment parameter, it 
cannot be made the sole basis of dose-response curve. 
B. The Manchester System 
31,32
 
The Manchester system is one of the oldest and the most 
extensively used systems in the world. It is characterized by doses to four 
points: point A, point B, a bladder point, and a rectum point. The duration 
of the implant is based on the dose rate calculated at point A, although the 
dose at the other points is taken into consideration in evaluating a 
treatment plan. With the availability of the treatment planning computers, 
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most users of the Manchester system examine the isodose distributions in 
the frontal and sagittal planes in addition to obtaining dose at the four 
designated points. Point A still remains the point of dose prescription. 
Point A was originally defined as 2 cm superior to the lateral 
vaginal fornix and 2 cm lateral to the cervical canal. Later, it was 
redefined to be 2 cm superior to the external cervical os (or cervical end 
of the tandem), and 2 cm lateral to the cervical canal. Point B is defined 3 
cm lateral to point A. 
Ideally, a point A represents the location where the uterine vessels 
cross the ureter. It is believed that the tolerance of these structures is the 
main limiting factor in the irradiation of the uterine cervix. Point B 
represents obturator node. 
 Original definition of points A and B, according to the Manchester 
system. 
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C. The    International     Commission     on     Radiation     Units     
and Measurements System
3
 
  The ICRU has recommended a system of dose specification that 
relates the dose distribution to the target volume, instead of the dose to a 
specific point. The dose is prescribed as the value of an isodose surface 
that just surrounds the target volume. 
DATA REQUIRED FOR REPORTING INTRACAVITARY 
THERAPY IN GYNECOLOGY (ICRU)
3
 
1. Description of the Technique: Minimum information should 
include the applicator type, source type and loading and orthogonal 
radiographs of the application. 
2. Total Reference Air Kerma. By this parameter, is meant the total 
air kerma strength of sources times the implant duration. This is 
similar to the total milligram-hours of radium or total mg-Ra eq-h 
except that the sources are calibrated in units of air kerma strength, 
that is, µGy m
2
 h
-1
. 
 3. Reference Volume. The reference volume is the volume of the 
isodose surface that just surrounds the target volume. The 
prescription isodose value of 60 Gy includes the dose contribution 
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from the external beam. The reference volume for the mtracavitary 
part of the treatment should be identified and its dimensions 
recorded. The figure below shows how the height (dh), width (dw), 
and thickness (dt) of the pear-shaped reference volume can be 
measured from the oblique frontal and oblique sagittal planes. The. 
reference volume is approximated by (dh x dw x dt). 
Plane a 
 
 
 
 
 
Plane b 
 
 
 
Determination of the reference isodose surface dimensions. Dw, width;  
dh, height; dt, thickness.
3
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1.       Absorbed Dose at Reference Points 
• Bladder Point: The bladder point is localized by using a Foley 
catheter, with the balloon filled with 7 ml of a contrast material. On 
the frontal radiograph, the bladder point is marked at the center of the 
balloon; on the lateral radiograph, the bladder point is obtained on a 
line drawn antero posteriorly through the center of the balloon, at the 
posterior surface. 
Rectal Point: The rectal point is identified on the frontal radiograph at 
the midpoint of the ovoid sources (or at the lower end of the 
intrauterine source). On the lateral radiograph, the rectal point is 
located on a line drawn from the middle of the ovoid sources, 5 mm 
behind the posterior vaginal wall. The posterior vaginal wall may be 
visualized by using radiopaque gauze for the vaginal packing. In our 
institute rectal catheter is inserted into rectal lumen to identify rectal 
reference point. 
 
 
 
 
Localization of bladder and rectum points-ICRU-38
3
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• Pelvic Wall Points: On the anteroposterior radiograph, the pelvic wall 
points are located at the intersection of a horizontal tangent to superior 
aspect of the acetabuliim and a vertical line touching the medial aspect 
of the acetabulum. On the lateral view, these points are marked as the 
highest middistance points of the right and left acetabulums. 
5.  Time dose pattern: The duration and time sequence of the implant 
relative to the external beam treatment should be recorded. 
In summary, the ICRU system of dose specification is probably the 
best that can be achieved at this time. Its greatest weakness however, is in 
the determination of reference volume. Further progress needs to be made 
in the determination and delineation of the target volume so that the 
cervix dose can be specified by the minimum target dose. 
CALCULATION OF DOSE DISTRIBUTION 
A modular approach has been proposed by the AAPM Task Group 
43 in which the effects of several physical factors on dose rate 
distribution are considered. 
Because anisotropy is not as serious a problem for 
192
Ir seeds as it 
is for 
125
I seeds, indium seeds may be treated as point sources in dose 
calculation formalism. For a point source, 
D(r) = Α  Sk (g(r)/r2) Φ an 
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Where   Α - dose rate constant, Sk - air kerma strength, g(r) - radial 
dose Junction, r-radial distance in Cm. Φ an - the   average anisotropy 
factor. It is defined as the ratio of 4pi averaged dose rate at a given radial 
distance divided-by the dose rate at the same distance along the 
transverse axis. Φan for 
192
Ir seeds may be equated to unity. 
DOSIMETRIC CHARACTERISTICS OF BRACHYTHERAPY 
SOURCES 
In general, four factors influence the single-source dose 
distribution for photon-emitting sources: (1) distance (inverse-square 
law); (2) absorption and scattering in the source core and encapsulation; 
(3) photon attenuation and (4) scattering in the surrounding medium. 
Each voxel of radioactive core material can be assumed to be an 
isotropic point source Because of the straight-line emission of photons in 
all directions, photon intensity or fluence, Φ (r), at any point is 
proportional to the inverse square of its distance, r: 
Φ (r)= no. incident photons/ unit area irradiated =no. photons 
emitted/4pir
2
  
α Dose (r) α Exposure (r) assuming that attenuation and scattering can be 
neglected. 
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To illustrate the derivation of inverse-square law, consider the 
source is surrounded by vacuum and placed at the centre of two 
concentric spherical surfaces of radii r1 and r2. By definition, an isotropic 
point source has no extension and radiates photons with equal likelihood 
in all directions in straight-line paths. As a result of this purely geometric 
effect, the absorbed doses D (r1) and D (r2) at the two distances r1 and r2 
are related by: 
 D (r1)/ D (r2) = Φ (r1)/ Φ (r2) = (r2/r1)
2
 
This fundamental law applies exactly to each point of the 
radioactive core of the source. However, above equation will not 
accurately describe the "collective" dose fall-off arising from the 
combined action of the point sources distributed throughout the core, 
unless both r1 and r2 are large relative to the active source dimensions. Of 
the four factors influencing the dose distribution inverse-square law is the 
most dominant. For a pure isotropic point source, dose will decrease by a 
factor of 100 between the distances of 0.5 and 5 cm. The influence of the 
remaining factors over the same distance range rarely exceeds a factor of 
2 or 3. Consequently, most of the clinical characteristics of implants can 
be accounted for by applying inverse-square law to each point like 
element of radioactivity within the implant. 
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The normal tolerance doses of various organs included in the 
treatment field are as follows - 
Uterus with cervix :  200 - 300Gy 
Vagina :  160-200Gy 
Bladder : 80Gy 
Rectum : 70Gy 
The tolerance of the rectum and bladder are the critical dose 
limiting points in the radiation of cancer cervix. 
RT REACTIONS 
EARLY REACTIONS: Include radiation proctitis, cystitis and ileitis. 
Usually they are mild and transient. Skin reactions vary from erythema, 
dry desquamation to moist desquamation and ulceration. Skin morbidity 
can be totally avoided by proper radio therapeutic techniques. 
LATE BLADDER -RTOG TOXICITY GRADING 
Grade 0 None 
Grade 1 Slight epithelial atrophy, Minor 
telengiectasia, Microscopic hematuria 
Grade 2 Moderate frequency, Moderate 
telengiectasia, Intermittent macroscopic 
hematuria 
Grade 3 Severe frequency & dysuria, Severe 
generalized telengiectasia (often with 
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petechiae), Frequent hematuria, Reduction in 
bladder capacity (<150 cc) 
Grade 4 Necrosis, contracted bladder (<100 cc), 
Severe hemorrhagic cystitis 
 
LATE RECTAL-RTOG TOXICITY GRADING 
Grade 0 None 
Grade 1 Mild diarrhea, mild cramping, bowel 
movement < 5 times daily. Slight rectal 
discharge or bleeding 
Grade 2 Moderate diarrhea, colic , bowel movement 
> 5 times daily. Excessive rectal mucous 
discharge or intermittent bleeding 
Grade 3 Obstruction or bleeding requiring surgery 
Grade 4 Necrosis, perforation ,Fistula 
 
FACTORS    INFLUENCING    LATE    BLADDER    AND    
RECTAL COMPLICATIONS 
There are many factors which influence bladder and rectal 
complications-Patient related factors and Treatment related factors. 
I.        PATIENT RELATED FACTORS 
1.       AGE OF THE PATIENT AND STAGE OF THE DISEASE 
Increased complication risk in older age group may be partially 
related to accompanying physiological changes and frequent medical 
conditions such as diabetes, hypertension and atherosclerosis.17 
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Additional risk, when treating with intracavitary brachytherapy, is created 
by age-related anatomical changes. 
Elzbieta Senkus-Konefka et al
26
 in their study observed that increasing 
patient age and disease stage resulted in the decreased frequency of use of 
large ovoids (both p<0.0001) and of long tandems (age : p=0.037, stage: 
p=0.004). As a result, higher doses to bladder (age: p0.0001, stage: 
p=0.017) and rectum (age: p =0.037, stage: p=0.011). 
2.       ASSOCIATED CO-MORBIDITIES 
• Willett et al
38
 reported on 28 patients with Irritable Bowel Disease 
(Crohn's disease, Ulcerative colitis) treated by conventional irradiation 
technique had 73%- 5 year actuarial rate of late toxicity. Patients 
treated by specialized techniques (to minimize large and small bowel 
radiation dose) had 23%- 5 year actuarial rate of late toxicity. 
• Roeske et al
29
 in his study had shown that Diabetes (p=0.03) is a 
significant factor affecting late rectal sequelae. 
II   TREATMENT RELATED FACTORS: 
Major factors affecting the late complications in HDR -ICBT are 
treatment related factors. 
1.       BIOLOGICAL EFFECTIVE DOSE (BED) 
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It plays an important role in late bladder and rectal complications. 
• Ferringo et al
27
 in his study observed that patients treated with 
cumulative BED at rectal point > 110 Gy3 and at bladder point > 
125Gy3 had a higher but not statistically significant 5-year actuarial 
rate of complications at these organs (18% vs. 12%, p=0.49 and 17% 
vs. 9%, P=0.20). 
• Brenda Clark et al in her study found out if the BED is above 125 
Gy3 the rectal complications rise sharply. 
2. HDR DOSE PER FRACTION 
• Orton et al
33
 in his meta-analysis has noted that fractionation of the 
HDR treatments significantly influenced toxicity: morbidity rates were 
significantly lower for Point A doses/ fraction <7 Gy compared with > 
7 Gy for both severe injuries (1.28%vs.  3.44%, p <0.001) and 
moderate plus severe (7.58% vs. 10.51%, p<0.001). 
• Wang et al
30
 in his prospective- study has shown that the 
complication rates for 2 groups (Group - 1 EBRT + 7.2 Gy / fraction 
to Point A for 3 fractions of HDR -4CBT, Group-2 EBRT + 4.8 Gy/ 
fraction to Point A for 5 fractions of HDR-ICBT). 
The actuarial proctitis rate for groups land 2 was 49.7% and 32.7% 
at 5-years and 50.5% and 32.7% at 10 years, respectively (p0.00l). Most 
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of the decrease in the rate of proctitis was a result of a decrease in the 
incidence of low grade proctitis (38% vs.22%) while high grade 
complications remained unchanged, 8% vs. 7%. The actuarial cystitis rate 
for groups land 2 was 14.3%vs. 11.4% at 5 years and 24.1% vs. 15% at 
10 years, respectively (p=0.134). 
3. EBRT TOTAL DOSE 
• Montana and Fowler
37
 in their study noted that the incidence of 
proctitis did increase with increasing dose of EBRT to whole pelvis. It 
ranged from 3% for dose < 20 Gy to whole pelvis to 14% with doses 
higher than 40 Gy (p=0.02). 
• ABS
27
 recommends whole pelvis RT of < 46 Gy when EBRT is 
combined with intracavitary brachytherapy. 
4.     EBRT TECHNIQUES 
• Yamazaki et al37 observed that 4 field whole pelvis RT (50 Gy) had 
significant lower rate of bowel complications than 2 parallel opposing 
fields (2.9% vs.17.5%, p< 0.05). 
5.  TOTAL RECTAL AND BLADDER DOSE 
• Montana GS , Fowler WC
37
 in their study showed that risk of 
proctitis increased as a function of rectal dose ranging from 2% for 
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patients receiving < = 50Gy to rectum to 18% for patients receiving 
>80Gy. 
• Grade 1 proctitis = 6810+ or - 906 cGy 
• Grade 3 proctitis =6997+or -1137 cGy, p=0.003 
Also dose response relationship was found between the rectal dose 
and severity of the complication 
The incidence of cystitis ranged from 3% for < 50 Gy to the 
bladder to 12% for >80 Gy or higher doses. 
• Perez et al
1b
 in his retrospective review of 1456 patients with 
carcinoma cervix treated with definitive irradiation (EBRT + 2 LDR 
insertions) reported that in bladder doses below 80Gy correlated with 
< than 3% incidence of morbidity and 5% with higher doses.(p=0.31). 
In recto sigmoid, the incidence of significant morbidity was < than 4% 
with doses below 75 Gy and increased to 9% with higher doses. 
Multivariate analysis showed that dose to rectal point and bladder 
point was the only factor influencing recto sigmoid and bladder 
sequelae respectively. 
7.       POINT A DOSE 
• Perez et al
1b
    in the same study showed that when the ratio of dose to 
the bladder or    rectum in relation to point A was 0.8 or less, the 
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incidence of  rectal morbidity was 2.5%   vs. 7.3% with higher ratios 
(p<=0.01); bladder morbidity was 2.3% vs. 5.8% respectively (p= 
0.02). 
• Roeske JC et al
29
 in his study noted that Point A dose (p=0.04) and 
conventional EBRT dose (p=0.03) were the most significant factors 
determining the late rectal sequelae.     
• The ABS
28
 has given recommendations to keep the dose to the 
nominal rectal and bladder points below 80% of the dose to Point A 
with HDR treatment protocols. 
WORLDWIDE SCENARIO 
Various imaging modalities like ultrasound. CT, MRI and PET 
scans etc have been explored in brachytherapy today. CT based 
Brachytherapy planning is more or les standard of care for most of the 
sites in the West. The advantages of CT based planning are accurate 
catheter reconstruction, better delineation of organ-at-risks (OAR’s) and 
documentation of dose volume parameters (DVH Parameters). However, 
the major disadvantage of inaccurate target volume delineation has paved 
way for MR based brachytherapy. MR imaging is becoming increasingly 
popular imaging modality for diagnosis and treatment planning for EBRT 
and BT. GYN GEC ESTRO Brachytherapy working group has 
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recommended contouring guidelines, concepts and terms in 3D Image 
Based treatment planning in cervical cancer branchytherapy. Recent 
reports from Vienna, Paris, Aarhus, Leuven etc. confirm the safety, 
feasibility and definite advantages of MR image based branchytherapy 
planning. Also there are reports from Vienna and Paris groups about the 
clinical outcome and late toxicities supporting the use of MR based 
branchytherapy with dose volume adaptation and escalation in locally 
advanced cervical cancers.   
INDIAN SCENARIO  
With advent of better imaging modalities, radiation technology and its 
successful implementation in external beam radiation therapy (3D CRT, 
IMRT, IGRT etc.,) is a success story today. However, implementation of 
these advances in branchytherapy has been rather sluggish. There are 
many ways to reduce the bladder and rectal complications. High precision 
radiotherapy techniques like 3DCRT, IMRT, IGRT, DART are evolving 
to deliver high radiation dose to the tumor and sparing the critical normal 
structures.  The study of Dr Umesh Mahantshetty et al
36
 (TMH) has 
stated that there is an urgent need to generate robust data on CT/MR 3D-
Image Based Brachytherapy to resolve the issue. In developing countries 
including India, locally advanced cervical cancer being a major problem, 
appropriate, adequate and quality treatment to all patients is the key to 
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success. In india, there has been a rapid rise in corporate and steady 
improvement in radiation facilities in government sectors. Most of the 
facilities have CT scanners / simulators for RT Planning. An attempt 
should be done by all high volume centres to incorporate some form of 
image based approach both for teletherapy and brachytherapy for cervical 
cancers from India is sparse but it does not preclude its use. There is an 
urgent to generate robost data on CT or MR 3D Image Based 
Brachytherapy Planning and suitable evidence through clinical studies to 
resolve the issues further in optimizing treatment for cervical cancers.    
REFERENCE STUDIES 
STUDY 1 
Comparison of conventional and CT-based planning for 
intracavitary brachytherapy for cervical cancer: target volume 
coverage and organs at risk doses Gungor Arslan et al 
(34)
  
In this study dosimetric data for 62 conventional and CT based 
ICBT plan of stage IB2, stage IIIB were analysed. 
The comparison was based on point doses defined by the ICRU 
and dose volume histograms (DVHs) from 3D planning. 
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PROCEDURE 
The treatment consists of EBRT 50.4 Gy (1.8 Gy/fr, daily, Monday 
through Friday) Brachytherapy was performed with a remote afterloading 
HDR unit with a radioactive Iridium 192 sources. The median amount of 
time between the completion of EBRT and the first brachytherapy 
application was 2 days (range 1-5 days). The planned dose per fraction 
was 7 Gy prescribed to point A, given in 4 fractions, and the 
Brachytherapy was delivered twice weekly. 
All patients underwent both conventional and 3D planning. CT 
compatible applicators were used in this study. A comparison of the 
conventional plan and CT plan was performed using the students t test. p 
value less than 0.05 were consider statistically significant.  
RESULT 
This study indicated that 3D maximum bladder and rectum values 
were 1.51 and 1.66 times greater than the ICRU reference bladder and 
rectum doses, respectively. (p = 0.07). This study demonstrate that CT 
guided brachytherapy planning is superior to conventional planning in 
evaluation of organ at risk bladder and rectum. 
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STUDY 2 
Comparison between CT and Orthogonal Based Calculation of  
ICRU Rectal and Bladder Doses During Intracavity Brachytherapy 
for Cervix Cancer- Are Orthogonal Films now Obsolete?
35
 
In the study of Alison Cameron at el 24 patients were analysed all 
patients had a CT scan of pelvis at 2 mm slice intervals and digitalized A-
P and lateral films taken. Standard plans were applied to these images, 
with the dose defined at point A, using the varian brachytherapy planning 
system (Brach vision). ICRU-38 Rectal and bladder points were 
identified and doses at these points recorded. The paired t-test was used 
to determine if there was statistically significant difference between the 
doses calculated in an individual patient using CT or orthogonal imaging.  
RESULTS 
24 patients were analysed. For the ICRU rectal point the mean dose 
difference was 4.02 (1.43-6.60; p<0.01) between CT and orthogonal 
based calculations of dose. Similarly the ICRU bladder point mean dose 
difference was 3.81 (1.48-15; p<0.01). 
The study states that there is a statistically significant difference 
between ICRU rectal and bladder doses when calculated with CT or 
orthogonal imaging of about 4%. Approximately 6% of patients receiving 
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radical radiotherapy of cervix cancer, despite being within dose 
constraints for ICRU bladder and rectal points, develop serious bowel or 
bladder toxicity. It is possible that some of this toxicity may be due to the 
inaccuracy in measurement of the ICRU bladder and rectal point from 
orthogonal images as documented in this report.  
STUDY 3 
Dosimetric evaluation of rectum and bladder using image-based CT 
planning and orthogonal radiographs with ICRU 38 
recommendations in intracavitary brachytherapy 
Swamidas V. Jamema, Sherly Saju, Umesh Mahantshetty et al
36
 
The purpose is to compare CT based dosimetry with International 
Commission on radiation Units and Measurements (ICRU 38) bladder 
and rectum reference points in patients of carcinoma of uterine cervix 
treated with intracavitary brachytherapy.  
PROCEDURE  
This study at Tata Memorial Hospital, Mumbai included 22 
patients of stage IIB and stage IIIB. All the patients were treated standard 
dose of external beam radiotherapy followed by ICA-HDR brachytherapy 
according to their institutional protocol. State IIB 7 Gy 5 fractions. Stage 
IIIB 7 Gy 3 fractions. Orthogonal radiographs and CT images were 
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acquired and transferred to PLATO planning system, bladder and rectal 
reference points were identified according to ICRU 38 recommendations. 
Dosimetry was carried out based on Manchester system. Patient treatment 
was done using 
192
Iridium high dose rate (HDR) remote after loading 
machine based on the conventional radiograph based dosimetry.  
RESULTS 
ICRU rectal and bladder point doses from the radiograph plans 
were compared with D2, dose received by 2cm
3
 of the organ receiving 
maximum dose from CT plan V2, volume of organ receiving dose more 
than the ICRU reference point, was evaluated. The mean volume of 
rectum and bladder was 60 (+ 28) cm
3
 and 138 (+ 41) cm
3
 respectively. 
The mean reference volume in radiograph and CT plan was 105 (+ 7) cm
3
 
and 107 (+7) cm
3
 respectively. It was found that 6 (+ 4) cm3 of rectum 
and 16 (+10) cm
3
 of bladder received dose more than the prescription 
dose V2 of rectum and bladder was 7 (+1.7) cm3 and 20.8  
(+6) cm
3
 respectively.  Mean D2 of rectum and bladder was found to be 
1.11 (+ 0.2) and 1.56 (+0.6) times the mean ICRU reference point 
respectively. This dosimetry study suggest that comparison of orthogonal 
X-ray based and CT based HDR ICA planning is feasible. ICRU rectal 
point dose correlates well with maximum rectal dose, while ICRU 
bladder point underestimates the maximum bladder dose. In our study 
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volumetric analysis was not undertaken as it is in this study. Only point 
based dosimetric analysis was done.  
Metal applicator used in the study produce streak artifacts in the 
CY images which make reconstruction of the applicator difficult which 
may lead to inaccurate applicator reconstruction. MRI/CT compatible 
applicators are expensive and not a s strong as metal applicators. Which 
prohibits the use of these expensive applicators in routine clinical practice 
especially in developing countries. Hence refinement of the existing 
applicators and development of new cost effective applicators and fast 
reconstruction methods with delineation of targets and critical structures 
are required for the implementation of image based brachytherapy in 
routine clinical practice. 
 
 
  
 AIM AND OBJECTIVE OF THE STUDY
 
To compare bladder and rectal radiation dose between
based dosimetry and CT based dosimetry.
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 orthogonal 
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MATERIALS AND METHODS 
STUDY PERIOD : From June 2010 to August 2010 
STUDY DESIGN  : Comparative descriptive study 
CASE SELECTION     :   Biopsy proven squamous cell Carcinoma 
cervix cases of stage IIB – IIIB who had 
completed EBRT and slated for HDR 
brachytherapy. 
NUMBER OF PATIENTS: 30 
INCLUSION CRITERIA 
 All eligible biopsy proven squamous cell carcinoma cervix 
patients, who had completed EBRT and slated for HDR 
Brachytherapy. 
  Stage II B – III B where HDR is contemplated. 
 Age: 30 - 60 years. 
 Performance Status: ECOG 0-1 histological proof from primary 
lesion. 
 Informed consent to be taken. 
 Patient should be fit for anesthesia. 
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EXCLUSION CRITERIA  
 Age > 60 years. 
 ECOG more than 2. 
 Patients not fit for anesthesia. 
 Patients with stage IV disease. 
 Histology other than squamous cell carcinoma. 
 History of prior radiotherapy / chemotherapy to Ca cervix. 
PRE-TREATMENT EVALUATION  
 History. 
 Physical examination with emphasis on gynaecological 
examination. 
 Biopsy. 
 LAB studies (CBE, LFT, RFT, VDRL, and HIV). 
 ECG. 
 Radiographic studies, 
 Chest X-ray. 
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 USG abdomen and pelvis to assess primary disease local extension, 
nodal status and visceral metastasis. 
 CT  Pelvis. 
 Cystoscopy. 
 Per speculum examination and by passing uterine sound to assess 
whether the patient is fit for intra cavity application. 
TREATMENT PROTOCOL  
 Conventional EBRT   - 50 Gy in 200c Gy per fraction 5 days a 
week 25 fraction. 
EBRT equipment : Co-60 Phoenix for Teletherapy 
Treatment portals : Ap and PA portals daily 
TREATMENT PLANNING EBRT 
The whole pelvis including the cervix,vagina and parametria with 
the pelvic and iliac group of nodes was treated.  
 RT PORTAL MARGINS FOR EBRT 
1.  Superior: L4-L5   interspace (to   include all the iliac and 
hypogastric   nodes). 
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2.  Inferior: If vagina is free - Lower margin of Obturator foramen. If 
vagina is involved - the entire vagina up to the introitus was 
included. 
3.  Lateral: 2 cm.lateral to bony pelvis. 
SIMULATION AND TREATMENT DELIVERY 
The treatment field was verified with PA simulator films in which 
the distal extension of the tumor was identified by placing a radio-opaque 
marker in the vagina. All patients were positioned in the prone position 
only with full bladder during external RT to exclude a greater extent of 
the small bowel from the treatment field. The AP portal was treated daily 
by gantry rotation of 180°. 
ICA PROTOCOL 
After teletherapy the patients were assessed for intracavitary 
application. Those found fit were subjected to high dose rate (HDR) 
Brachytherapy. 
HDR BRACHYTHERAPY PROTOCOL 
 Technique Remote after loading with Iridium-192 source  
Machine HDR- micro Selectron  
Activity 2- 10 Ci 
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Intracavitary applicator Modified Fletcher Suit applicator with tandem 
15° and ovoids 30° angulations. 
No. of #s TWO (1# -1 week after EBRT, 2# -1 week after 
1#) 
 Dose delivered to Point A 800cGy /# -2#  
Total Dose to point A    86.7Gy (LDR equivalent). 
LQED     81 Gy 
Total BED to rectum  126Gy2.5 and  bladder 140Gy2.5 
PROCEDURE 
I.V. Sedation with ketamine, patient in lithotomy position the 
perineum and upper half of the thighs were cleaned and draped. Per 
vaginal examination was done. Urinary bladder was catheterized and 7ml. 
of diluted contrast (urograffin 3ml. +distilled water 4ml.) was injected 
into the Foley balloon. Uterine sound was introduced and uterine length 
assessed. The cervical stopper was adjusted according to the uterine 
length and fixed. The tandem was introduced into cervix and ovoids into 
vaginal formic and secured. Adequate vaginal packing was done in a 
conventional manner with adequate gauze to displace the bladder and 
rectum and to secure the applicators in position. Rectal catheter with 
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radio opaque marker was introduced into the rectum to find out the 
anterior rectal wall. A tape sling tied to the abdomen externally was used 
to further secure the apparatus in position.   
Patient shifted to simulator room. Orthogonal X-rays AP and 
lateral were taken.  
Subsequently the films were digitized and dose calculations were 
obtained using Nucletron Plato brachytherapy Treatment Planning 
System. The dose was prescribed to Point -A. 
DOSE SPECIFICATIONS 
Point A and Point B were defined according to Manchester system 
of dose definition. The bladder and rectal reference points defined by 
ICRU 38 were used to calculate the bladder and rectal point dose before 
and after inflation. Additional points for rectum were also taken for dose 
calculations to get a better idea of dose received by rectum.  
Four additional rectal points were taken 1 cm above and below the 
usual rectal reference points. 
Conventional dosimetry 
 Orthogonal radiographs (anterior-posterior and lateral) were taken 
on a conventional simulator with radioopaque markers in the 
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applicators. The cervical stopper is identified in Orthogonal film 
and used as origin radiographs were reconstructed and the 
treatment planning was done using PLATO planning system.  
 Source positions were loaded according to the standard loading 
pattern in accordance with the Manchester system. Point A was 
defined on the radiographs as being 2 cm superior to the cervical 
stopper (flange) and 2 cm lateral from the axis of the intrauterine 
tandem. Bladder and rectal reference points were identified 
according to ICRU 38 recommendations.  
 In addition to the ICRU rectal reference point, four additional 
rectal points were defined at 1 cm interval superior and inferior to 
the ICRU rectal reference point . 
 The dose was prescribed to point A, treatment was carried out 
using Iridium HDR remote after-loading machine based on the 
conventional radiograph-based dosimetry. 
CT-based ICA-HDR dosimetry 
 All the above intracavitary applications were simultaneously taken 
up for CT planning. CT scans of 3-mm slice-thickness were 
obtained, 4 cm above the tandem superiorly and to the level of anus 
inferiorly.  
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 Rectum and bladder were delineated. Rectum was contoured from 
recto-sigmoid junction superiorly till ischial tuberosity inferiorly. 
The entire bladder was contoured. The cervical stopper is identified 
in 3D using the INSIGHT Software. In the INSIGHT software the 
CT cuts were reconstructed to form a 3D image. The cervical 
stopper was used as origin. Treatment planning was carried out 
using PLATO planning system.  
 Point A, ICRU rectal and bladder reference points were identified 
on CT planning. For each application, the corresponding optimized 
source positions used in radiograph-based planning were 
duplicated for CT image-based planning.  
Reconstruction of metal applicators using CT images was difficult 
due to the presence of artifacts. 
All bladder and rectal point doses were individually and 
cumulatively assessed. Statistical analyses was done. The results were 
obtained.  
Evaluation: Conventional vs. CT-based dosimetry correlation  
 Cumulative dose volume histogram (cDVH) was calculated for 
every plan with 1,00,000 calculation points randomly placed in 
volume of interest.  
 51
 To compare the respective ICRU rectal and bladder point doses 
with the 3D volume dose, the minimum dose value in the 2.0cc 
volume receiving the highest dose (D2) was determined from 
DVHs for bladder rectum. D2 is the dose received by 2cm
3 
volume 
of bladder/rectum. This is calculated from the cumulative Dose 
Volume Histogram (cDVH) from 3D planning. 
 The comparison and correlation of doses to bladder and rectum was 
carried out using D2 and the ratio of D2 to ICRU reference point 
doses.  
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CASE RESULTS AND ANALYSIS 
From June 2010 to August 2010 Total of 30 cases of locally 
advanced cancer cervix patients were included in the study. 
Characteristics 
1. Age 
Age (Year) Number of cases 
31-40 3 (10%) 
41-50 15 (50%) 
51-60 12 (40%) 
 
In this study we enrolled patients between 30-60 years of age. Majority of 
patients were distributed in the age group of 4
th
 and 5
th
 decades. (Fig. 1) 
2. FIGO stage grouping 
Stage Grouping Number of cases 
II B 23 
III A 0 
III B  7 
 
Majority of the patients in the study belong to FIGO stage II B. 
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Statistical analysis was performed by paired t-test comparing the doses of 
bladder and rectum in orthogonal x-rays and CT. 
PARAMETRIC TEST 
To compare the means of two sets of scores, the t-test should be 
used. Since we were comparing the scores of the same respondents on 
two variables, the within-subjects (paired samples) t-test was used. The 
paired t-test involves taking the difference between the two scores for 
each respondents and finding the mean of these difference scores. The 
value of the t-statistics was shown, with its degrees of freedom (df) and 
its probability level (sig 2 tail). If the probability was less than 0.001, we 
concluded that there was a statistically significant difference between the 
means of the two sets of scores.   
EVALUATION 
Conventional vs. CT-based dosimetry correlation  
Cumulative dose volume histogram (cDVH) was calculated for every 
plan with 1,00,000 calculation points randomly placed in volume of 
interest. D2 is the dose received by 2 cm
3 
volume of bladder/rectum. D2 is 
calculated from cDVH. The comparison and correlation of doses to 
bladder and rectum was carried out using D2 and the ratio of D2 to ICRU 
reference point doses.  
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In this study following were analysed. 
Dose received by ICRU reference point from orthogonal radiograph 
based plan and D2 from cDVH of CT image based plan for bladder and 
rectum.  
Organ D2 Gy 
Dose to ICRU 
point Gy 
D2 /Dose to 
ICRU  
ratio 
Bladder 5.41 3.22 1.69 + (0.20) 
Rectum 4.98 3.71 1.36 + (0.25) 
D2 is the dose received by the 2cm
3
 of the volume of critical structure, bladder and 
rectum. Values given in bladder and rectum or for standard deviation.  
The mean D2 of bladder and ICRU bladder point was 5.41 and 3.22. 
While for rectum it was 4.98 Gy and 3.71 respectively. Mean D2 of 
bladder and rectum was found to be 1. 69 and 1.36 times the mean ICRU 
reference points respectively. This mean difference was statistically 
significant (p<0.001). 
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RESULTS 
εD2 / ε dose to ICRU reference points 
Bladder - D2 /dose to ICRU reference points Ratio - 1.69 (p<0.001) 
Rectum - D2 /dose to ICRU reference points Ratio - 1.36 (p<0.001) 
INFERENCE 
2D underestimates the bladder dose 
2D underestimates the rectal dose 
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DISCUSSION 
Traditionally, dosimetry of ICA for carcinoma cervix was based on 
orthogonal radiographs with ICRU 38 recommendations, which allow the 
evaluation of point doses such as manchester points A, B, ICRU rectal 
and bladder reference points. Orthogonal radiographs provide spatial 
information of the applicator with respect to bony structures. However, 
his time tested system has a limitation of computing the doses received by 
the volumes of the critical structures as this has only 2D value. Over the 
past two decades, there have been significant advances in imaging USG, 
CT, MRI, PET scan. With an advantage of determine the dose volume 
parameters for the critical structures. We undertook this dosimetric study 
to compare, validate and document the correlation between point based 
doses to rectum and bladder with the conventional standard ICRU 38 
rectal and bladder points.  
In the present study we demonstrated that more precise analysis on 
the dose received by certain volume of (2cm
3
) of organ at risk, bladder 
and rectum can be accomplished by utilizing cumulative Dose Volume 
Histogram (CDHs) on CT plan, which may be of critical importance in 
regard to normal tissue tolerance limits.  
The dose to ICRU bladder reference point does not correlate with 
the maximum dose from the CT planning. Mean D2 was found to be 1.69 
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+ 0.20 times the mean ICRU bladder reference points. These results agree 
with the other studies published in the literature, where the ICRU bladder 
reference point underestimated the maximum dose by two to three times.  
The dose to ICRU rectal point from the radiograph based planning 
does not correlate with maximum dose from CT Planning. Mean D2 of 
rectum was found to be 1.36 + 0.25 times the mean ICRU rectal reference 
point, suggesting that there was significant difference between the 
radiograph based ICRU rectal point and CT based estimation of the 
parameter D2.   
ICRU rectal reference point underestimated the maximum dose, 
and the ratio of the maximum dose and the ICRU rectal dose reported 
varies in the range of 1.4-2.8
14 16
 The large variation reported may be 
attributed to several factors such as different types of applicators used. 
Inter observer variability in contouring of critical structures etc., Saarnak 
et al
16
 reported significant inter observer variability in the contouring of 
critical structures in patients treated with ICBT for carcinoma cervix.  As 
we used rectal catheter which is in the rectal luman the ICRU reference 
point dose in 2D is lesser than the D2 value.  
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The advent of better imaging modalities, radiation technology and 
its successful implementation in external beam radiation therapy is a 
success story today. However implementation of these advances in 
brachytherapy has been rather sluggish. Various imaging modalities like 
ultrasound CT, MRI and PET scans etc have been explored in 
brachytherapy today.  Imaging modalities have been invaluable in 
improving the quality of brachytherapy offered to cancer patients. Their 
introduction has led to improvements in treatment planning, 
implementation and assessment, resulting in efficacy and tolerability 
benefits for patients. CT based Branchytherapy planning is more or less 
standard of care for most of the sites in the West. The advantages of CT 
based planning are accurate catheter reconstruction, better delineation of 
organ-at-risks (OAR) and documentation of dose volume parameters 
(DVH Parameters). However, the major disadvantage of inaccurate target 
volume delineation has paved way for MR based Branchytherapy. MR 
imaging is becoming increasingly popular imaging modality for diagnosis 
and treatment planning for EBRT and BT. GYN GEC ESTRO 
Branchytherapy working group has recommended contouring guidelines, 
concepts and term in 3D image based treatment planning in cervical 
cancer brachytherapy. Recent reports from Vienna, Paris, Aarhus, Leuven 
etc., Confirm the safety, feasibility, and definite advantages of MR image 
based Branchytherapy Planning. Also, there are reports from Vienna and 
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Paris groups about the clinical outcome and late toxicities supporting the 
use of MR based Branchytherapy with dose volume adaptation of 
escalation in locally advanced cervical cancers.   
WORLDWIDE SCENARIO  
 MRI is used to plan the intracavitary approaches. Internal treatment 
is currently performed according to the GEC ESTRO 
recommendations for image guided 3D gynecological 
brachytherapy with defined constraints for tumor coverage and the 
doses to the organs at risk. 
 ICRU 38 guidelines is used to generate standard plan. 
 MR scans with special applicators in situ are made, allowing 
delineation of target and organs at risk.   
 With this information 3D optimization is performed with respect to 
the given constraints.  
COMPARING OUR STUDY WITH REFERENCE STUDY 
In the reference study of Gungor Arslan et al
34
. The maximum 
rectum and bladder doses in 3D were 1.66 and 1.51 times greater than the 
ICRU reference rectum and bladder values respectively. Our study 
correlates well with this study. 
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In the study of Alison Cameron et al
35
 there is a statistically 
significant difference between ICRU rectal and bladder doses when 
calculated with CT or orthogonal imaging of about 4%. This study 
correlates well with our study. 
Swamidas V. Jamema, Umesh Mahantshetty et al
36
 study states 
that comparison of orthogonal X-ray and CT-based HDR ICA planning is 
feasible. ICRU rectal point dose correlates well with maximum rectal 
dose in 3D, while ICRU bladder point underestimates the maximum 
bladder dose. Further, incorporation of newer imaging modalities, 
refinements in applicators and planning systems and wider acceptability 
of conformal brachytherapy may revolutionize brachytherapy practice in 
carcinoma cervix.  In our study volumetric analysis was not done. Only 
point based study was done. 
In this study radio opaque gauze packing in both anterior and 
posterior was used to displace the bladder and rectum from the vaginal 
applicator.  The use of radiopaque pack in the vagina of enabled accurate 
definition of ICRU rectal point and contouring of anterior rectal wall. As 
we used rectal catheter which is in the rectal luman the ICRU reference 
point dose in 2D is lesser than the D2 value.  
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LIMITATIONS OF THE PROCEDURE 
The successful implementation of image based dosimetry for 
intracavitary brachytherapy for carcinoma of cervix depends on the 
accurate delimeation of the critical structures and the target volume. The 
use of metal applicators in the present study produced artifacts that made 
delineation of the critical structures difficult to some extent.  
RECOMMENDATIONS 
• Use of CT compatible applicators for better delineation of organ at 
risk like bladder and rectum. As a result we can escalate the dose to 
the target. 
• In vivo dosimetry can be done to accurate measurement of bladder and 
rectal doses.  
• Weekly fraction of HDR can be consider as soon as patient is fit for 
ICBT for better local disease control.  
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CONCLUSION 
Radiotherapy is an effective treatment modality for carcinoma 
cervix. HDR brachytherapy is incorporated along with EBRT in the 
treatment protocols.  
Our study suggested that maximum bladder and rectal 3D values 
were 1.69 and 1.36 times greater than the ICRU reference bladder and 
rectal doses respectively.  
Bladder - D2 /dose to ICRU reference point Ratio - 1.69 (p<0.001 
Statistically significant) 
Rectum - D2 /dose to ICRU reference point Ratio - 1.36 (p<0.001 
Statistically significant) 
2D underestimates bladder dose 
2D underestimates the rectal dose 
3D - Image based brachytherapy is the standard of care for locally 
advanced CA cervix patients in western countries. However, image based 
brachytherapy, is not widely used in developing countries in routine 
clinical practice due to various limitations. Further, incorporation of 
newer imaging modalities, refinements in applicators and planning 
systems and wider acceptability of conformal brachytherapy may 
revolutionize brachytherapy practices in carcinoma cervix in Government 
setups in developing countries.  
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